These inhibitors, including anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death receptor-1 (PD-1), or its ligand (PD-L1) induced T cell activation mechanisms to mediate anti-tumor response, and thus has been used for the treatment in multiple cancers [2, 3]. This evidence concerns the gene CD274 and neoplasm.